$Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need$

Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need

Recent years have seen significant improvement in chronic lymphocytic leukemia (CLL) management. Targeting B-cell lymphoma (BCL-2) and Bruton’s kinase (BTK) have become the main strategies to restrain CLL activity. These agents are generally well tolerated, but the discontinuation of these therapies...

Full description

Bibliographic Details
Main Authors:	Przemysław Zygmunciak, Tadeusz Robak, Bartosz Puła
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	International Journal of Molecular Sciences
Subjects:	BCL-2 inhibitors BTK inhibitors BTK degraders CAR-T PI3K inhibitors chronic lymphocytic leukemia
Online Access:	https://www.mdpi.com/1422-0067/25/3/1589

Similar Items

Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia
by: Hayama M, et al.
Published: (2024-03-01)

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
by: Jing Zhang, et al.
Published: (2022-04-01)

Editorial: Novel targeted drugs for indolent lymphoid malignancies
by: Tadeusz Robak, et al.
Published: (2023-06-01)

Current Treatment Options in CLL
by: Moritz Bewarder, et al.
Published: (2021-05-01)

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
by: Cao T, et al.
Published: (2022-11-01)

Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors
by: Nkolika Nwankwo, et al.
Published: (2024-01-01)

Current and future treatment strategies in chronic lymphocytic leukemia
by: Krish Patel, et al.
Published: (2021-04-01)

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
by: Rhodes JM, et al.
Published: (2021-03-01)

Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
by: Rory Bennett, et al.
Published: (2023-07-01)

A History of Targeted Therapy Development and Progress in Novel–Novel Combinations for Chronic Lymphocytic Leukemia (CLL)
by: Matthew Karr, et al.
Published: (2023-02-01)

Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
by: Erika Rimondi, et al.
Published: (2021-07-01)

Critical molecular pathways in CLL therapy
by: Gerardo Ferrer, et al.
Published: (2018-03-01)

Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review
by: Andrea Visentin, et al.
Published: (2024-03-01)

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
by: Philipp von Hundelshausen, et al.
Published: (2021-03-01)

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
by: Natalia Timofeeva, et al.
Published: (2023-05-01)

Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia
by: Mihaela Andreescu, et al.
Published: (2023-04-01)

Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
by: Jorge J Castillo, et al.
Published: (2023-02-01)

Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
by: Issei Nakade, et al.
Published: (2023-11-01)

The TKI Era in Chronic Leukemias
by: Danilo De Novellis, et al.
Published: (2021-12-01)

p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
by: Federica Giordano, et al.
Published: (2019-06-01)

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
by: Stefano Molica, et al.
Published: (2023-07-01)

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
by: Marzia Palma, et al.
Published: (2021-07-01)

Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID‐19 infection: Case report and literature review
by: Adam Yuh Lin, et al.
Published: (2020-11-01)

Bowel, lung, and retinal ischemia: Rare manifestations of leukostasis syndrome in a man with chronic lymphocytic leukemia—A case report and review of the literature
by: Bowen He, et al.
Published: (2023-09-01)

Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma
by: Ying Zhou, et al.
Published: (2022-12-01)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
by: Xianhui Wang, et al.
Published: (2021-07-01)

Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity
by: Hyewon Cho, et al.
Published: (2020-10-01)

BTK, the new kid on the (oncology) block?
by: Emanuela Grassilli, et al.
Published: (2022-08-01)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
by: Madelyn Burkart, et al.
Published: (2022-03-01)

BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells
by: Weibo Kong, et al.
Published: (2021-11-01)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
by: Timothy L. Chen, et al.
Published: (2021-02-01)

A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia
by: Audrey L. Smith, et al.
Published: (2022-06-01)

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
by: Rula Zain, et al.
Published: (2021-07-01)

Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton’s Tyrosine Kinase Inhibitor
by: Keun Woo Lee, et al.
Published: (2020-04-01)

Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
by: Datong Zhang, et al.
Published: (2021-08-01)

Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor
by: Malarz K, et al.
Published: (2023-03-01)

The role of ibrutinib in COVID-19 hyperinflammation: A case report
by: Suzanne Maynard, et al.
Published: (2021-04-01)

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
by: Tadeusz Robak, et al.
Published: (2022-02-01)

Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?
by: Marina Deodato, et al.
Published: (2022-10-01)

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
by: Yuting Yan, et al.
Published: (2023-07-01)